PMID- 17452902
OWN - NLM
STAT- MEDLINE
DCOM- 20070525
LR  - 20171116
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 83
IP  - 8
DP  - 2007 Apr 27
TI  - Regulatory T-cells in the graft and the risk of acute graft-versus-host disease 
      after allogeneic stem cell transplantation.
PG  - 1107-13
AB  - BACKGROUND: FOXP3+ regulatory T-cells (Treg) are important regulators of 
      allo-reactivity and may therefore represent an important predictor for the risk 
      of graft versus-host disease (GVHD) after allogeneic stem cell transplantation. 
      METHODS: To determine the clinical significance of Treg-content in stem cell 
      grafts, we analyzed 58 human leukocyte antigen (HLA)-identical sibling donors (34 
      patients received myeloablative and 24 patients reduced intense conditioning 
      regimens) and correlated the Treg frequency with clinical outcome after stem cell 
      transplantation (SCT). RESULTS: A mean value of 9.1 x 10(6) CD4+ FOXP3+ Treg per 
      kg body weight (bw) of the recipient was transplanted (ranging from 0.7 to 33.7 x 
      10(6) Treg/kg bw). Graft content of Treg correlated with mononuclear cells and 
      CD3+ T-cells. Patients receiving low numbers of Treg (Treg(low)) after 
      myeloablative conditioning for SCT had a significantly increased cumulative 
      incidence of 76% for acute GVHD when compared with 23% for individuals receiving 
      high numbers of Treg (Treg(high)). This observation, however, was not made in 
      patients after reduced intense conditioning-SCT. Notably, relapse rate was not 
      significantly different between Treg(low) and Treg(high) patients in either 
      patient group and overall survival was even increased in Treg(high) patients 
      after myeloablative SCT. Finally, low Treg graft levels represent an independent 
      prognostic factor in multivariate analysis for the appearance of acute GHVD. 
      CONCLUSION: Donor-derived Treg might be of particular significance for the 
      development of acute GVHD after myeloablative SCT using HLA-identical sibling 
      donors.
FAU - Wolf, Dominik
AU  - Wolf D
AD  - Clinical Division of Hematology and Oncology, Medical University Innsbruck, 
      Innsbruck, Austria. dominik.wolf@i-med.ac.at
FAU - Wolf, Anna Maria
AU  - Wolf AM
FAU - Fong, Dominic
AU  - Fong D
FAU - Rumpold, Holger
AU  - Rumpold H
FAU - Strasak, Alexander
AU  - Strasak A
FAU - Clausen, Johannes
AU  - Clausen J
FAU - Nachbaur, David
AU  - Nachbaur D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (CD3 Complex)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - CD3 Complex/immunology/metabolism
MH  - Cell Proliferation
MH  - Female
MH  - Graft vs Host Disease/*immunology
MH  - *Hematopoietic Stem Cell Transplantation/statistics & numerical data
MH  - Humans
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Myoblasts/immunology
MH  - Recurrence
MH  - Risk Factors
MH  - Survival Rate
MH  - T-Lymphocytes, Regulatory/cytology/*immunology
MH  - Transplantation Conditioning
EDAT- 2007/04/25 09:00
MHDA- 2007/05/26 09:00
CRDT- 2007/04/25 09:00
PHST- 2007/04/25 09:00 [pubmed]
PHST- 2007/05/26 09:00 [medline]
PHST- 2007/04/25 09:00 [entrez]
AID - 00007890-200704270-00019 [pii]
AID - 10.1097/01.tp.0000260140.04815.77 [doi]
PST - ppublish
SO  - Transplantation. 2007 Apr 27;83(8):1107-13. doi: 
      10.1097/01.tp.0000260140.04815.77.